The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes. Methods In this multicentre, double-blind, randomised controlled trial, patients aged 6-45 years recently diagnosed with type 1 diabetes were randomly assigned (2:1) to receive abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years. Computer-generated permuted block randomisation was used, with a block size of 3 and stratified by participating site. Neither patients nor research personnel were aware of treatment assignments. The primary outcome was baseline-adjusted geometric mean 2-h area-under-the-curve (AUC) serum C-peptide concentration after a mixed-meal tolerance test at 2 years' follow-up. Analysis was by intention to treat for all patients for whom data were available. This trial is registered at ClinicalTrials.gov, NCT00505375. Findings 112 patients were assigned to treatment groups (77 abatacept, 35 placebo). Adjusted C-peptide AUC was 59% (95% CI 6·1-112) higher at 2 years with abatacept (n=73, 0·378 nmol/L) than with placebo (n=30, 0·238 nmol/L; p=0·0029). The difference between groups was present throughout the trial, with an estimated 9·6 months' delay (95% CI 3·47-15·6) in C-peptide reduction with abatacept. There were few infusion-related adverse events (36 reactions occurred in 17 [22%] patients on abatacept and 11 reactions in six [17%] on placebo). There was no increase in infections (32 [42%] patients on abatacept vs 15 [43%] on placebo) or neutropenia (seven [9%] vs five [14%]). Interpretation Co-stimulation modulation with abatacept slowed reduction in β-cell function over 2 years. The beneficial effect suggests that T-cell activation still occurs around the time of clinical diagnosis of type 1 diabetes. Yet, despite continued administration of abatacept over 24 months, the decrease in β-cell function with abatacept was parallel to that with placebo after 6 months of treatment, causing us to speculate that T-cell activation lessens with time. Further observation will establish whether the beneficial effect continues after cessation of abatacept infusions. Funding US National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, the fusion protein CTLA4-Ig (abatacept) preserved stimulated C-peptide concentration for only 9 months despite continuous intravenous administration for 2 years.138”
From Type 1 diabetes (2014) · cites this paper as [138]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Disappointingly, after promising phase 1–2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.135–141”
From Type 1 diabetes (2014) · cites this paper as [138]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Abatacept has also been shown to preserve Cpeptide when administered soon after the onset of clinical type 1 diabetes, 19”
From The future of type 1 diabetes therapy (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citation
Cited by
Sorted by citations
Items 201–300 of 615
Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
the Type 1 Diabetes TrialNet Study Group, Wentworth, J. M., the Immune Tolerance Network Study Group, Bediaga, N. G., Giles, L. C., Ehlers, M. R., Gitelman, S. E., Geyer, S. M., Evans‐Molina, C., & Harrison, L. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4722-z · Cited by 30
Self-citationEnforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Linsley, P. S., & Long, S. A. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000488 · Cited by 30
Clinical Immunologic Interventions for the Treatment of Type 1 DiabetesPreprint
Chatenoud, L., Warncke, K., & Ziegler, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007716 · Cited by 32
Mechanistic basis of immunotherapies for type 1 diabetes mellitus
Chen, W., Xie, A., & Chan, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.017 · Cited by 32
Current Status on Immunological Therapies for Type 1 Diabetes Mellitus
Xin, G. L. L., Yap, P. K., Ying, T., Chellian, J., Gupta, G., Kunnath, A. P., Nammi, S., Collet, T., Hansbro, P. M., Dua, K., et al. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1144-3 · Cited by 30
Endotypes in T1D: B lymphocytes and early onset
Smith, M. J., Cambier, J. C., & Gottlieb, P. A. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000547 · Cited by 28
Self-citationLong-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts
Wang, Y., Dorrell, C., Naugler, W. E., Heskett, M. B., Spellman, P. T., Li, B., Galivo, F., Haft, A., Wakefield, L., & Grompe, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.014 · Cited by 29
CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease
Bassi, R., Fornoni, A., Doria, A., & Fiorina, P. (2015) · Diabetologia · doi:10.1007/s00125-015-3766-6 · Cited by 27
Progress and challenges for treating Type 1 diabetes
Garyu, J., Meffre, E., Cotsapas, C. J., & Herold, K. C. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.04.004 · Cited by 30
Redox-Dependent Inflammation in Islet Transplantation Rejection
Barra, J. M., & Tse, H. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00175 · Cited by 29
Tavira, B., Barcenilla, H., Wahlberg, J., Achenbach, P., Ludvigsson, J., & Casas, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9391845 · Cited by 28
Lessons and gaps in the prediction and prevention of type 1 diabetes
Mameli, C., Triolo, T. M., Chiarelli, F., Rewers, M., Zuccotti, G., & Simmons, K. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106792 · Cited by 33
Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development
Vudattu, N. K., & Herold, K. C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.881797 · Cited by 28
Hanes, W. M., Olofsson, P. S., Kwan, K., Hudson, L., Chavan, S. S., Pavlov, V. A., & Tracey, K. J. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00142 · Cited by 27
Zenz, S., Mader, J. K., Regittnig, W., Brunner, M., Korsatko, S., Boulgaropoulos, B., Magnes, C., Raml, R., Narath, S. H., Eller, P., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01836 · Cited by 29
Type 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 32
Unmet needs in the treatment of autoimmunity: from aspirin to stem cells.
Chang, C. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.052 · Cited by 26
A complex auxiliary: IL-17/Th17 signaling during type 1 diabetes progression
Zheng, Z., & Zheng, F. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.007 · Cited by 27
Liu, Y., Powrie, J., Arif, S., Yang, J. H. M., Williams, E., Khatri, L., Joshi, M., Lhuillier, L., Fountoulakis, N., Smith, E., et al. (2022) · Diabetes · doi:10.2337/db21-0728 · Cited by 28
Therapeutic Potential of Regulatory T cells in Autoimmune Disorders
Fessler, J., Felber, A., Duftner, C., & Dejaco, C. (2013) · BioDrugs · doi:10.1007/s40259-013-0026-5 · Cited by 27
Mbunwe, E., der Auwera, B. J. R. V., Vermeulen, I., Demeester, S., Dalem, A. V., Balti, E. V., Aken, S. V., Derdelinckx, L., Dorchy, H., Schepper, J. D., et al. (2012) · Diabetes · doi:10.2337/db12-0747 · Cited by 27
Critical role of rabphilin‐3A in the pathophysiology of experimental lymphocytic neurohypophysitis
Yasuda, Y., Iwama, S., Kiyota, A., Izumida, H., Nakashima, K., Iwata, N., Ito, Y., Morishita, Y., Goto, M., Suga, H., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5046 · Cited by 27
Weir, G. C., Ehlers, M. R., Harris, K. M., Kanaparthi, S., Long, A., Phippard, D., Weiner, L. J., Jepson, B. M., McNamara, J., Koulmanda, M., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12660 · Cited by 27
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Ylescupidez, A., Bahnson, H. T., O’Rourke, C., Lord, S. M., Speake, C., & Greenbaum, C. J. (2023) · Nature Communications · doi:10.1038/s41467-023-42581-z · Cited by 29
Self-citationTherapies to Preserve β-Cell Function in Type 1 Diabetes
Ludvigsson, J. (2015) · Drugs · doi:10.1007/s40265-015-0511-x · Cited by 29
Bioengineering strategies for inducing tolerance in autoimmune diabetes
Bækkeskov, S., Hubbell, J. A., & Phelps, E. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.007 · Cited by 26
New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes
Cabello-Olmo, M., Araña, M., Radichev, I., Smith, P., Huarte, E., & Barajas, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194789 · Cited by 28
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
Deligne, C., You, S., & Mallone, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040542 · Cited by 26
Felton, J. L., Griffin, K., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Evans‐Molina, C., DiMeglio, L. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00357-y · Cited by 27
Self-citationHeterogeneity in recent‐onset type 1 diabetes – a clinical trial perspective
Bollyky, J., Xu, P., Butte, A. J., Wilson, D. M., Beam, C. A., Greenbaum, C. J., & Type 1 Diabetes TrialNet Study Group (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2643 · Cited by 25
Self-citationInhibition of Islet Immunoreactivity by Adiponectin Is Attenuated in Human Type 1 Diabetes
Pang, T., Chimen, M., Goble, E., Dixon, N. C., Benbow, A., Eldershaw, S. E., Thompson, D., Gough, S. C. L., & Narendran, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3516 · Cited by 26
Pinckney, A., Rigby, M. R., Keyes-Elstein, L., Soppe, C. L., Nepom, G. T., & Ehlers, M. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.032 · Cited by 26
Zhang, W., Gorantla, V. S., Campbell, P. G., Li, Y., Yang, Y., Komatsu, C., Weiss, L. E., Zheng, X. X., & Solari, M. G. (2016) · Diabetes · doi:10.2337/db16-0320 · Cited by 26
Making progress: preserving beta cells in type 1 diabetes
GALLAGHER, M. P., Goland, R., & Greenbaum, C. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06321.x · Cited by 26
Self-citationImmune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes
Simmons, K. M., Gottlieb, P. A., & Michels, A. W. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0793-8 · Cited by 26
Self-citationCD28: A New Drug Target for Immune Disease
Xia, S., Chen, Q., & Niu, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666191114102830 · Cited by 26
Immune interventions to preserve β cell function in type 1 diabetes
Ehlers, M. R. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000227 · Cited by 28
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
Martinov, T., & Fife, B. T. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14106 · Cited by 28
Type 1 Diabetes Immunotherapy: Is the Glass Half Empty or Half Full?
Herold, K. C., & Bluestone, J. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002981 · Cited by 24
Interleukin-7 and Type 1 Diabetes
Monti, P., & Bonifacio, E. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0518-9 · Cited by 24
From immunobiology to β-cell biology: The changing perspective on type 1 diabetes
Maganti, A. V., Evans‐Molina, C., & Mirmira, R. G. (2014) · Islets · doi:10.4161/isl.28778 · Cited by 24
Strategies for clinical trials in type 1 diabetes
Ehlers, M. R. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.008 · Cited by 25
Sims, E. K., & DiMeglio, L. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.010 · Cited by 22
Self-citationWang, C., & Tsai, H. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i3.238 · Cited by 25
Immunotherapy for type 1 diabetes
Allen, L. A., & Dayan, C. M. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldab027 · Cited by 24
Anderson, R. L., DiMeglio, L. A., Mander, A., Dayan, C. M., Linsley, P. S., Herold, K. C., Marinac, M., & Ahmed, S. T. (2022) · Diabetes Care · doi:10.2337/dc22-0308 · Cited by 24
Self-citationNew therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.835 · Cited by 23
Mayer, L., Kaser, A., & Blumberg, R. S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.015 · Cited by 24
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes
Buckner, J. H., & Nepom, G. T. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.02.009 · Cited by 23
A model‐based approach to sample size estimation in recent onset type 1 diabetes
Bundy, B. N., Krischer, J. P., & Type 1 Diabetes TrialNet Study Group (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2800 · Cited by 23
Self-citationEmerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes
Greenbaum, C. J., Lord, S. M., & VanBuecken, D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0932-x · Cited by 24
Self-citationTargeted immune interventions for type 1 diabetes
Rigby, M. R., & Ehlers, M. R. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000075 · Cited by 24
Non-antigenic and antigenic interventions in type 1 diabetes
Rydén, A. K., Wesley, J. D., Coppieters, K. T., & von Herrath, M. G. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26890 · Cited by 23
Krishnamurthy, B., Selck, C., Chee, J., Jhala, G., & Kay, T. W. H. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.018 · Cited by 23
Stem Cell Therapy and Type 1 Diabetes Mellitus: Treatment Strategies and Future Perspectives
Farooq, T., Rehman, K., Hameed, A., & Akash, M. S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_195 · Cited by 22
Targeting Type 1 Diabetes: Selective Approaches for New Therapies
Sheehy, D. F., Quinnell, S. P., & Vegas, A. J. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01118 · Cited by 23
A quantitative measure of treatment response in recent‐onset type 1 diabetes
Bundy, B. N., Krischer, J. P., & for the Type 1 Diabetes TrialNet Study Group (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.143 · Cited by 21
Self-citationXin, L., Jiang, T. T., Chaturvedi, V., Kinder, J. M., Ertelt, J. M., Rowe, J. H., Steinbrecher, K. A., & Way, S. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402336111 · Cited by 21
Wang, C. J., Petersone, L., Edner, N. M., Heuts, F. W. H., Ovcinnikovs, V., Ntavli, E., Kogimtzis, A., Fabri, A., Elfaki, Y., Houghton, L. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34477-1 · Cited by 21
Tooley, J., & Herold, K. C. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000076 · Cited by 23
The Compelling Case for Anti-CD3 in Type 1 Diabetes
Skyler, J. S. (2013) · Diabetes · doi:10.2337/db13-1157 · Cited by 21
Self-citationTargeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance
Mackern‐Oberti, J. P., Vega, F., Llanos, C., Bueno, S. M., & Kalergis, A. M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150916381 · Cited by 21
Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics
You, S., & Chatenoud, L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3139-2_8 · Cited by 22
The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes
Coppieters, K. T., & von Herrath, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00283 · Cited by 21
Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy
Siddiqui, K., & Nawaz, S. S. (2023) · ImmunoTargets and Therapy · doi:10.2147/itt.s417917 · Cited by 22
TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial
Bazile, C. A., Abdel-Malik, M. M., Ackeifi, C., Anderson, R. L., Beck, R. W., Donath, M. Y., Dutta, S., Hedrick, J. A., Karpen, S. R., Kay, T. W. H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1470677 · Cited by 21
Mallone, R., Bismuth, É., Thivolet, C. H., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., & Beltrand, J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101603 · Cited by 23
Shapiro, M. R., Tallon, E. M., Brown, M. E., Posgai, A. L., Clements, M. A., & Brusko, T. M. (2024) · Diabetologia · doi:10.1007/s00125-024-06339-6 · Cited by 20
Gorus, F., Keymeulen, B., Veld, P. I. '., & PIPELEERS, D. G. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.856757 · Cited by 20
Zala, A., & Thomas, R. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac115 · Cited by 20
Marriott, C. L., Carlesso, G., Herbst, R., & Withers, D. R. (2015) · European Journal of Immunology · doi:10.1002/eji.201445421 · Cited by 20
Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus
He, B., Li, X., Yu, H., & Zhou, Z. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12286 · Cited by 20
Couri, C. E. B., Oliveira, M. C., & Simões, B. P. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0309-0 · Cited by 20
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes
Foster, T. P., Bruggeman, B., & Haller, M. J. (2025) · Drugs · doi:10.1007/s40265-025-02150-8 · Cited by 24
A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus
Ebrahimpour, Y., Khatami, S. M., Saffar, M., Fereidouni, A., Biniaz, Z., Erfanian, N., & Fereidouni, M. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70120 · Cited by 21
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 21
Desai, R. J., Dejene, S. Z., Jin, Y., Liu, J., & Kim, S. C. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11124 · Cited by 19
Santopaolo, M., Sullivan, N., Thomas, A. C., Alvino, V. V., Nicholson, L. B., Gu, Y., Spinetti, G., Kallikourdis, M., Blom, A. W., & Madeddu, P. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609406 · Cited by 20
Staging the progression to type 1 diabetes with prediagnostic markers
Sosenko, J. M. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000267 · Cited by 21
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Fleming, G. A., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160413115655 · Cited by 19
A little help from residual β cells has long-lasting clinical benefits
Lam, A. P., Dayan, C. M., & Herold, K. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143683 · Cited by 19
Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge
Caldara, R., Tomajer, V., Monti, P., Sordi, V., Citro, A., Chimienti, R., Gremizzi, C., Catarinella, D., Tentori, S., Paloschi, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323439 · Cited by 19
Lin, C., Hu, S., Cai, X., Lv, F., Yang, W., Liu, G., Yang, X., & Ji, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107157 · Cited by 18
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials
Thomas, H. R., & Gitelman, S. E. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12040 · Cited by 18
Self-citationBioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases
Yu, C., Xi, J., Li, M. C., An, M., & Liu, H. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00632 · Cited by 20
Felix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 18
Mathieu, C., Wych, J., Hendriks, A. E. J., Van Ryckeghem, L., Tree, T., Chmura, P., Möller, C., Casteels, K., Danne, T., Reschke, F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01674-5 · Cited by 17
Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes
Jung, S., Nasr, M. B., Bahmani, B., Usuelli, V., Zhao, J., Sabiu, G., Seelam, A. J., Naini, S. M., Balasubramanian, H. B., Park, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202300812 · Cited by 18
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., van der Meer, I. M., Cattaneo, S. G. D. A., Ruggenenti, P. L., & Remuzzi, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_33 · Cited by 17
Wang, X., Leveson-Gower, D. B., Gołąb, K., Wang, L., Marek-Trzonkowska, N. M., Krzystyniak, A., Wardowska, A., Millis, J. M., Trzonkowski, P., & Witkowski, P. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.02.015 · Cited by 17
Stuijver, D. J. F., Romualdi, E., van Zaane, B., Bax, L., Buller, H. R., Gerdes, V. E. A., & Squizzato, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1168-2 · Cited by 17
Blasetti, A., Giulio, C. D., Tumini, S., Provenzano, M., Rapino, D., Comegna, L., Prezioso, G., Chiuri, R. M., Franchini, S., Chiarelli, F., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.6 · Cited by 17
Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities
Beik, P., Ciesielska, M., Kucza, M., Kurczewska, A., Kuźmińska, J., Maćkowiak, B., & Niechciał, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092805 · Cited by 18
Trials in the Prevention of Type 1 Diabetes: Current and Future
Wherrett, D. K. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.004 · Cited by 17
Self-citationCope, A. P. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.08.005 · Cited by 16
Teplizumab’s immunomodulatory effects on pancreatic β-cell function in type 1 diabetes mellitus
Kokori, E., Olatunji, G. D., Ogieuhi, I. J., Aboje, J. E., Olatunji, D., Aremu, S. A., Igwe, S. C., Moradeyo, A. A., Ajayi, Y. I., & Aderinto, N. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00181-w · Cited by 18
Prospects for therapeutic tolerance in humans
Baker, K. F., & Isaacs, J. D. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000029 · Cited by 15
Regulation of Diabetogenic Immunity by IL-15–Activated Regulatory CD8 T Cells in Type 1 Diabetes
Stocks, B. T., Wilson, C., Marshall, A. F., Hoopes, E. M., & Moore, D. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800976 · Cited by 17
Chen, S. K., Lee, H., Jin, Y., Liu, J. L., & Kim, S. C. (2020) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaa027 · Cited by 16
Steck, A. K., Liu, X., Krischer, J. P., Haller, M. J., Veijola, R., Lundgren, M., Ahmed, S. T., Akolkar, B., Toppari, J., Hagopian, W., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa715 · Cited by 17
Self-citation
Metadata
- Authors
- Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., Moran, A., Raskin, P., Rodriguez, H., Russell, W. E., Schatz, D., Wherrett, D., Wilson, D. M., Krischer, J. P., & Skyler, J. S.
- Affiliations
- Joslin Diabetes Center (US)
- University of South Florida (US)
- University of Pittsburgh (US)
- Indiana University School of Medicine (US)
- University of California, San Francisco (US)
- Columbia University (US)
- Benaroya Research Institute (US)
- University of Miami (US)
- Children's Hospital Los Angeles (US)
- University of Minnesota (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- University of Florida (US)
- University of Toronto (CA)
- Stanford University (US)
- Corresponding author
- Skyler, Jay S
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 378
- Issue
- 9789
- Pages
- 412-419
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3462593
- OpenAlex
- W2154694193
- Cited by
- 612
- References
- 31
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 30 · 2022: 33 · 2021: 34 · 2020: 43 · 2019: 32 · 2018: 41 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 46 · 2013: 57 · 2012: 45
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Sanofi
- University of Florida
- University of Washington
- MacroGenics
- Novo Nordisk
- National Institutes of Health (5ul1rr031986-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, U01DK061040, U01DK085461, U01DK085505, U01DK085499, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK085504, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, U01DK085509, U01 DK-061016)
- U.S. National Library of Medicine (HHSN267200800019C)
- National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- abatacept, type 1 diabetes, recent-onset type 1 diabetes, T cell costimulation, T cell-mediated autoimmunity, C-peptide, beta-cell function, immunomodulation, mixed meal tolerance test, infusion-related adverse events, infection, neutropenia, children and adolescents, disease progression, HLA-DR
- MeSH terms
- Abatacept, Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, T-Lymphocytes, Autoimmunity, Randomized Controlled Trials as Topic, Immunoconjugates, Insulin-Secreting Cells, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
